CervoMed (CRVO) reported a key senior leadership hire to oversee the Company’s Chemistry, Manufacturing, and Controls division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches. Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical Operations, in June 2025. Dr. Verwijs was previously Chief Technical Officer at Adipo Therapeutics and has significant experience developing drugs, from the pre-clinical stage through NDA and commercial launch.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Releases New Business and Financial Information
- CervoMed’s Strategic Advancements and Market Opportunities Drive Buy Rating
- CervoMed’s Promising Future: Buy Rating Backed by Strong Pipeline and Financial Position
- CervoMed Inc. Reports Q1 2025 Financial Results
- CervoMed Announces $50M Sales Agreement with Leerink